Glucotrack Files Amendment on Equity Sales
Ticker: GCTK · Form: 8-K/A · Filed: Jan 14, 2025 · CIK: 1506983
Sentiment: neutral
Topics: amendment, equity-securities, unregistered-sales
TL;DR
Glucotrack filed an 8-K/A amendment on Jan 14, 2025, for unregistered equity sales on Jan 6, 2025.
AI Summary
Glucotrack, Inc. filed an amendment (8-K/A) on January 14, 2025, regarding unregistered sales of equity securities that occurred on January 6, 2025. The filing details transactions related to the company's equity, but specific details on the nature or value of these unregistered sales are not provided in this excerpt.
Why It Matters
This amendment provides updated information on equity transactions, which could impact the company's capital structure and shareholder equity.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings, especially concerning unregistered equity sales, can indicate complex financial maneuvers or potential dilution, requiring closer scrutiny.
Key Players & Entities
- Glucotrack, Inc. (company) — Registrant
- January 6, 2025 (date) — Date of earliest event reported
- January 14, 2025 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- 001-41141 (identifier) — SEC File Number
FAQ
What specific type of equity securities were sold in the unregistered offering?
The filing excerpt does not specify the type of equity securities involved in the unregistered sales.
What was the date of the earliest event reported in this amendment?
The earliest event reported was on January 6, 2025.
When was this amendment (8-K/A) filed with the SEC?
This amendment was filed on January 14, 2025.
What is Glucotrack, Inc.'s state of incorporation?
Glucotrack, Inc. is incorporated in Delaware.
What is the SEC file number for Glucotrack, Inc.?
The SEC file number for Glucotrack, Inc. is 001-41141.
Filing Stats: 762 words · 3 min read · ~3 pages · Grade level 13.5 · Accepted 2025-01-14 07:50:20
Key Financial Figures
- $0.001 — s") to purchase common stock, par value $0.001 per share of the Company. Beginning o
Filing Documents
- form8-ka.htm (8-K/A) — 41KB
- 0001493152-25-002027.txt ( ) — 213KB
- gctk-20250106.xsd (EX-101.SCH) — 3KB
- gctk-20250106_lab.xml (EX-101.LAB) — 33KB
- gctk-20250106_pre.xml (EX-101.PRE) — 22KB
- form8-ka_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 14, 2025 GLUCOTRACK, INC. By: /s/ Paul Goode Name: Paul Goode Title: Chief Executive Officer